Trillium Reports First Quarter 2017 Financial and Operating

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
124
Trillium Reports First Quarter 2017 Financial and Operating Results

TORONTO, ONTARIO--(Marketwired - May 12, 2017) - Trillium Therapeutics Inc. (TSX:TRIL)(NASDAQ:TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today provided a corporate update and reported financial results for the three months ended March 31, 2017.

"With continued strong recruitment at eight clinical sites across North America, we were recently able to provide preliminary observations from our TTI-621 trial in hematologic malignancies," said Dr. Niclas Stiernholm, president and CEO of Trillium Therapeutics. "We find it encouraging to see that TTI-621 appears to have activity both in a single agent setting and in combination with rituximab. We look forward to providing additional details at an upcoming scientific conference by year-end."

Corporate Update:

  • In April 2017, the company reported preliminary data from the expansion phase of its TTI-621 (SIRPaFc) clinical trial where 3 of 6 patients in the TTI-621/ rituximab combination cohort who have had at least one interval PET/CT restaging obtained partial metabolic responses, as demonstrated by decreased tumor activity on PET/CT scans, and one patient in the AML cohort with minimal residual disease obtained a complete molecular remission.
  • In February, Trillium presented additional pharmacology data from its ongoing Phase 1a/1b trial of TTI-621 at the ASCO-SITC Clinical Immuno-Oncology Symposium. These data suggest that:
    • repeat weekly dosing of TTI-621 leads to a longer half-life and accumulation of circulating drug, overcoming the platelet antigen sink;
    • the transient decrease in platelets observed immediately following TTI-621 exposure was attenuated in most patients receiving multiple infusions;
    • compared to the initial infusion, the extent and duration of CD47 occupancy on peripheral leukocytes was elevated following the sixth dose suggesting increased receptor occupancy on circulating leukemic blast cells; and
    • increases in cytokines associated with macrophage activation are consistent with rapid engagement of the innate immune system.
  • In January, Trillium initiated dosing in its second Phase 1 clinical trial with TTI-621 in patients with relapsed or refractory percutaneously-accessible solid tumors and mycosis fungoides. To our knowledge, the patients in this trial are the first to ever receive an intratumoral injection of a CD47 blocking agent.
  • Trillium announced the expansion of its CD47 franchise with plans to advance its second SIRPaFc fusion protein, TTI-622, into clinical testing with the filing of an IND submission by the end of 2017. TTI-622 contains an IgG4 Fc region and is thus anticipated to have a different pharmacologic profile and enable greater exposures in patients than TTI-621 (IgG1 Fc). Like TTI-621, TTI-622 does not bind human erythrocytes, and the company believes that this property could give TTI-622 best-in-class status among IgG4-based CD47 blocking agents currently in development.

First Quarter 2017 Financial Results

(Amounts in Canadian dollars)

As of March 31, 2017, Trillium had cash and marketable securities of $41.3 million compared to $50.5 million at December 31, 2016. The decrease in cash for the period was due mainly to the use of $8.8 million for operations.

Net loss for the three months ended March 31, 2017 of $11.5 million was higher than the loss of $7.2 million for the three months ended March 31, 2016. The net loss was higher due mainly to increased research and development program expenses of $2.8 million, higher personnel costs of $0.3 million, higher intangible asset amortization of $0.2 million related mainly to the acquisition of Fluorinov intangible assets, and a deferred tax recovery in the three months ended March 31, 2016 related to the acquisition of Fluorinov of $3.7 million. The increased expense was partially offset by a lower net foreign currency loss in 2017 of $0.4 million from holding US denominated cash with a depreciating US dollar compared to $3.6 million for the comparable prior year period.

Selected Consolidated Financial Information:

Consolidated statements of loss and comprehensive loss
Amounts in Canadian dollars Three months ended March 31, 2017 Three months ended March 31, 2016
Research and development expenses $10,198,592 $6,378,672
General and administrative expenses 954,493 1,037,517
Net finance costs 296,996 3,474,993
Income tax expense (recovery) 2,044 (3,686,447 )
Net loss and comprehensive loss for the period 11,452,125 7,204,735
Basic and diluted loss per common share (1.46 ) (0.92 )
Consolidated statements of financial position
Amounts in Canadian dollars As at March 31, 2017 As at December 31, 2016
Cash and marketable securities 41,347,180 50,472,971
Total assets 57,040,314 66,622,691
Total equity 47,173,722 58,119,519

About Trillium Therapeutics

Trillium Therapeutics Inc. is a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer. The company's lead program, SIRPaFc (TTI-621), is a fusion protein that consists of the CD47-binding domain of human SIRPa linked to the Fc region of a human immunoglobulin (IgG1). It is designed to act as a soluble decoy receptor, preventing CD47 from delivering its inhibitory ("do not eat") signal. Neutralization of the inhibitory CD47 signal enables the activation of macrophage anti-tumor effects by pro-phagocytic ("eat") signals. A Phase 1 clinical trial ( NCT02663518 ) evaluating SIRPaFc is ongoing in advanced hematologic malignancies, and a second Phase 1 trial is underway in solid tumors ( NCT02890368 ). TTI-622 is an IgG4 SIRPaFc protein, which is primarily being developed for combination therapy. An IND filing is targeted for 2H/17. Trillium also has a proprietary medicinal chemistry platform, using unique fluorine chemistry, which permits the creation of new chemical entities from validated drugs and drug candidates with improved pharmacological properties. Stemming from this platform, the company's most advanced preclinical program is an orally-available bromodomain inhibitor, followed by an epidermal growth factor receptor antagonist with increased uptake in the brain. In addition, a number of compounds directed at undisclosed immuno-oncology targets are currently in the discovery phase.

For more information visit: www.trilliumtherapeutics.com

Caution Regarding Forward-Looking Information

This press release contains forward-looking statements within the meaning of applicable United States securities laws and forward looking information within the meaning of Canadian securities laws (collectively, "forward-looking statements"). Forward-looking statements in this press release include statements about, without limitation, Trillium's belief that one monotherapy AML patient obtained a complete molecular remission, and that 3 of the 6 TTI-621/rituximab combination cohort patients assessed by PET/CT restaging experienced partial metabolic responses, and our expectation that TTI-621 meaningfully contributed to the combination treatment. With respect to the forward-looking statements contained in this press release, Trillium has made numerous assumptions regarding, among other things: the effectiveness and timeliness of preclinical and clinical trials; and the completeness, accuracy and usefulness of the data. While Trillium considers these assumptions to be reasonable, these assumptions are inherently subject to significant scientific, business, economic, competitive, market and social uncertainties and contingencies. Additionally, there are known and unknown risk factors that could cause Trillium's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements contained in this press release. Known risk factors include, among others: positive preliminary results from early-stage clinical trials may not be indicative of the final results from the trial or be indicative of favorable outcomes in later-stage clinical trials and data are subject to audit for inclusion in the final clinical trial database; clinical data may not demonstrate adequate efficacy and safety to result in regulatory approval to market any of our product candidates in any jurisdiction; given the early stage of Trillium's product development, there can be no assurance that its research and development programs will result in regulatory approval or commercially viable products and that Trillium can adequately demonstrate TTI-621's individual contribution in a combination therapy; clinical trials may be more costly or take longer to complete than anticipated, and may never be initiated or completed, or may not generate results that warrant future development of the tested drug candidate; Trillium may not receive the necessary regulatory approvals for the clinical development of Trillium's products; economic and market conditions may worsen; and market shifts may require a change in strategic focus. A more complete discussion of the risks and uncertainties facing Trillium appears in Trillium's Annual Report on Form 20-F and Trillium's continuous disclosure filings, which are available at www.sedar.com and at www.sec.gov . All forward-looking statements herein are qualified in their entirety by this cautionary statement, and Trillium disclaims any obligation to revise or update any such forward-looking statements or to publicly announce the result of any revisions to any of the forward-looking statements contained herein to reflect future results, events or developments, except as required by law.

Neither TSX nor its Regulation Services Provider (as that term is defined in the policies of the TSX) accepts responsibility for the adequacy or accuracy of this release.

James Parsons Chief Financial Officer Trillium Therapeutics Inc. 416-595-0627 x232 james@trilliumtherapeutics.com www.trilliumtherapeutics.com Mark Corbae Canale Communications for Trillium Therapeutics 619-849-5375 mark@canalecomm.com
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Radiology Staffing Gap Deepens as Imaging Demand Rises

Updated Category News Views 112

An imaging order does not mean much if nobody is available to read it, and that plain operational fact sits at the center of Medicus Healthcare Solutions' 2026 report on the radiologist shortage. The report's projected gap of 2,450 full-time-equivalent radiologists in 2027 is troubling enough. Its estimate of a 4,130 FTE shortfall by 2032 is the part that should make...

Continue Reading
Shenzhen's Vertical Factories Put Robotics on Fast Track

Updated Category News Views 26

A truck climbing to a ninth-floor factory is the sort of detail that cuts through the usual innovation fog. Shenzhen's Honghualing industrial base in Nanshan is built around that odd-looking reality: keep engineers, component makers, automated lines and test customers stacked close together, then squeeze time out of the process. For anybody watching robotics, LiDAR and...

Continue Reading
Lummus-Versalis Deal Adds Nine Elastomer Technologies

Updated Category News Views 187

Nine elastomer technologies do not make a flashy headline, yet this is the sort of chemical-industry move that can matter long after the applause dies down. Lummus Technology and Versalis have expanded their partnership to cover nine elastomer technologies. That is the disclosed fact, and it is meaningful on its own. The release does not lay out contract value, duration,...

Continue Reading
Fox Hill Steel Marks a Long Public-Building Road Ahead

Updated Category News Views 70

A signed steel beam is a fine civic moment, but it is not the finish line. Burlington’s new Fox Hill Elementary School has reached its topping-off milestone, with the structural steel now in place for a 91,000-square-foot, two-story facility intended to serve roughly 325 kindergarten-through-fifth-grade students. That is tangible progress, the sort nobody can fake with...

Continue Reading
Texas Restaurants Get a New Read on Customer Demand

Updated Category News Views 195

Texas restaurant owners are being handed a sharper flashlight, and frankly it is overdue. HundredX and the Texas Restaurant Association have launched a pilot that gives TRA members access to the HundredX Restaurant Insights Platform, aiming to bring customer and market intelligence to the independent operators and regional chains that usually cannot pay big-company prices...

Continue Reading
ArchiPro Enters U.S. Design Market With Curated Bet

Updated Category News Views 56

Blue-chip furniture and glossy project photos are not a moat by themselves, no matter how hard a platform tries to make them look like one. But ArchiPro’s full U.S. launch deserves a closer look because it arrives with something many would-be marketplace operators lack: more than a decade of operating history in New Zealand and Australia. A Three-Sided Machine Meets...

Continue Reading
Another Nine's A9OS Puts Software at Center of Golf

Updated Category News Views 100

A golf simulator chain is trying to turn the boring plumbing into its sharpest club. Another Nine’s A9OS is not merely a booking widget dressed up for a franchise brochure; it is meant to run the whole 24/7 operation, from payments and door access to cameras, simulator support and guest help. That ambition deserves attention because this is exactly where a staff-free...

Continue Reading
Watson Motion Tests Military Pretrial Confinement Rules

Updated Category News Views 170

Military confinement fights are rarely neat, and this one comes with a short clock but plenty of unanswered questions. Defense lawyers for U.S. Air Force Maj. Jason Watson argued on Nov. 17 that he should be released from pretrial confinement while his case proceeds. A military judge is ordinarily expected to issue a ruling within 14 days of the hearing, under the court's...

Continue Reading
Leatt Sets Its Virtual 2026 Shareholder Meeting Date

Updated Category News Views 73

A calendar notice is not a catalyst, but ignoring the calendar is how shareholders miss the small moments that matter. Leatt Corporation has scheduled its 2026 virtual annual general meeting of stockholders for Friday, November 20, at 11:00 AM Eastern Time. For holders of OTCQB:LEAT, this is a basic corporate-governance event, not a new product launch or a financial...

Continue Reading
Esquire Spotlight Puts Trauma Cleanup Work in Focus

Updated Category News Views 96

A national magazine profile is an odd milestone for a business built around other people’s worst days. David Lesaffre, co-owner and operator of T.A.C.T. 48, T.A.C.T. AZ, and T.A.C.T. Fort Worth, has been featured by Esquire in a piece called “The Trauma Cleaners.” The attention is deserved, frankly, because biohazard remediation is one of those necessary services...

Continue Reading

Top 5 Most Recently Viewed Articles

Strategies for Investing During Market Peaks Explained

Updated Category News Views 291

Understanding Market Behaviors: Peaks and Investment Strategies The stock market has a tendency to rise over time. Historically, whether viewed through six-month, one-year, or even five-year lenses, the S&P 500 has consistently produced positive returns. This pattern holds true even as the market reaches record highs, a phenomenon that has drawn attention from analysts....

Continue Reading
Holborn Assets Launches Innovative App for Wealth Management

Updated Category News Views 212

Holborn Assets Introduces a Cutting-Edge Financial App In a significant move that underscores its commitment to digital transformation, Holborn Assets has rolled out an innovative app aimed at optimizing wealth management for its clients. This comprehensive financial management solution is specifically designed to provide users with seamless access to their financial...

Continue Reading
Growth of Mobivity's Connected Rewards in the Retail Sector

Updated Category News Views 137

Enhancing Customer Engagement with Connected Rewards Mobivity Holdings Corp. (OTCQB: MFON) has recently witnessed a remarkable surge in its Connected Rewards technology adoption among convenience store retailers. This significant development highlights how effective customer engagement solutions can reshape the retail landscape, particularly during the recent quarter. A...

Continue Reading
Coherent Boosts Silicon Carbide Production for AI and Datacenters

Updated Category News Views 192

Coherent Enhances Its Silicon Carbide Platform Coherent Corp. (NYSE: COHR), a global leader in photonics, has recently made significant strides in its development of silicon carbide (SiC) technology to meet the growing thermal efficiency needs of artificial intelligence in datacenter infrastructures. This advancement represents a major milestone for the company in its...

Continue Reading
World Bank's Commitment to Bangladesh: Over $2 Billion for Reforms

Updated Category News Views 140

World Bank Commits Over $2 Billion to Bangladesh The World Bank has recently made a major announcement regarding financial support for Bangladesh, pledging more than $2 billion for the current fiscal year. This funding is designed to help accelerate ongoing reform efforts, improve response to natural disasters, and enhance healthcare services and air quality throughout...

Continue Reading